Argos swings for a $60M IPO in the shadow of Dendreon’s struggles

Damian Garde

North Carolina's Therapeutics believes it can succeed where Dendreon has faltered, pitching a $ 60 million IPO that would help the biotech get its personalized cancer therapy through Phase III.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS